Ookawara M[au] - Search Results

Year	Number of Results
2016	1
2019	1
2020	3
2021	3
2022	1

1

Phosphodiesterase 4 inhibitors in diabetic nephropathy.

Ookawara M, Nio Y. Ookawara M, et al. Cell Signal. 2022 Feb;90:110185. doi: 10.1016/j.cellsig.2021.110185. Epub 2021 Nov 14. Cell Signal. 2022. PMID: 34785349 Review.

2

Protective effect of a novel phosphodiesterase 4 selective inhibitor, compound A, in diabetic nephropathy model mice.

Ookawara M, Nio Y, Yamasaki M, Kuniyeda K, Hanauer G, Tohyama K, Hazama M, Matsuo T. Ookawara M, et al. Eur J Pharmacol. 2021 Mar 5;894:173852. doi: 10.1016/j.ejphar.2021.173852. Epub 2021 Jan 8. Eur J Pharmacol. 2021. PMID: 33422506

3

Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats.

Koyama R, Ookawara M, Watanabe M, Moritoh Y. Koyama R, et al. Among authors: ookawara m. Mol Pharmacol. 2021 Apr;99(4):286-293. doi: 10.1124/molpharm.120.000168. Epub 2021 Feb 5. Mol Pharmacol. 2021. PMID: 33547250

4

Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety.

Furukawa H, Miyamoto Y, Hirata Y, Watanabe K, Hitomi Y, Yoshitomi Y, Aida J, Noguchi N, Takakura N, Takami K, Miwatashi S, Hirozane Y, Hamada T, Ito R, Ookawara M, Moritoh Y, Watanabe M, Maekawa T. Furukawa H, et al. Among authors: ookawara m. J Med Chem. 2020 Sep 24;63(18):10352-10379. doi: 10.1021/acs.jmedchem.0c00843. Epub 2020 Sep 9. J Med Chem. 2020. PMID: 32900194

5

Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKA^y mice.

Nio Y, Ookawara M, Yamasaki M, Hanauer G, Tohyama K, Shibata S, Sano T, Shimizu F, Anayama H, Hazama M, Matsuo T. Nio Y, et al. Among authors: ookawara m. FASEB J. 2020 Nov;34(11):14997-15014. doi: 10.1096/fj.202001084R. Epub 2020 Sep 16. FASEB J. 2020. PMID: 32939821

6

The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight.

Ookawara M, Matsuda K, Watanabe M, Moritoh Y. Ookawara M, et al. J Pharmacol Exp Ther. 2020 Oct;375(1):21-27. doi: 10.1124/jpet.120.000046. Epub 2020 Jul 27. J Pharmacol Exp Ther. 2020. PMID: 32719069

7

SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.

Ueno H, Ito R, Abe SI, Ookawara M, Miyashita H, Ogino H, Miyamoto Y, Yoshihara T, Kobayashi A, Tsujihata Y, Takeuchi K, Watanabe M, Yamada Y, Maekawa T, Nishigaki N, Moritoh Y. Ueno H, et al. Among authors: ookawara m. J Pharmacol Exp Ther. 2019 Aug;370(2):172-181. doi: 10.1124/jpet.118.255885. Epub 2019 Jun 10. J Pharmacol Exp Ther. 2019. PMID: 31182471

8

Successful Treatment of Hemifacial Spasm Caused by an Ectatic Vertebral Artery Accompanying Agenesis of the Carotid Artery.

Takeda R, Ookawara M, Fushihara G, Kobayashi M, Fujimaki T. Takeda R, et al. Among authors: ookawara m. Surg J (N Y). 2016 Sep 22;2(3):e105-e107. doi: 10.1055/s-0036-1593447. eCollection 2016 Jul. Surg J (N Y). 2016. PMID: 28825001 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results